|Bid||11.15 x 100|
|Ask||16.50 x 100|
|Day's Range||14.15 - 14.60|
|52 Week Range||14.15 - 33.00|
|PE Ratio (TTM)||-12.23|
|Earnings Date||Jul 26, 2017 - Jul 31, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||26.38|
Biogen Inc. (BIIB) announced that the conditional marketing authorization for its drug Fampyra for improvement of walking in multiple sclerosis (MS) patients in the EU has been converted to a standard marketing approval.
Acorda Therapeutics, Inc. will present new data from the Phase 3 clinical trial of INBRIJATM at the International Congress of Parkinson’s Disease and Movement Disorders , being held in Vancouver, British Columbia from June 4-8, 2017.
Acorda Therapeutics, Inc. will present at the Deutsche Bank 42nd Annual Healthcare Conference in Boston on Thursday, May 4, 2017 at 11:20 a.m. EDT.